Aigen Investment Management, LP Editas Medicine, Inc. Transaction History

Aigen Investment Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$4.67 - $7.28 $154,833 - $241,368	33,155 New	33,155 $154,000
Q4 2023 Feb 09, 2024	BUY	$6.25 - $11.11 $370,056 - $657,811	59,209 New	59,209 $599,000
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $75,022 - $135,300	11,796 New	11,796 $97,000
Q3 2021 Nov 12, 2021	SELL	$39.27 - $72.94 $148,362 - $275,567	-3,778 Closed	0 $0
Q2 2021 Aug 10, 2021	SELL	$31.29 - $56.64 $191,338 - $346,353	-6,115 Reduced 61.81%	3,778 $214,000
Q1 2021 May 11, 2021	BUY	$39.71 - $90.58 $392,851 - $896,107	9,893 New	9,893 $416,000
Q3 2020 Nov 06, 2020	SELL	$28.06 - $37.16 $518,969 - $687,274	-18,495 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$18.5 - $34.34 $342,157 - $635,118	18,495 New	18,495 $547,000
Q1 2020 May 08, 2020	SELL	$14.88 - $32.78 $48,538 - $106,928	-3,262 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$19.49 - $32.63 $63,576 - $106,439	3,262 New	3,262 $97,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $87.3M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.